---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-139573"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2021-11-16T23:59:59+00:00"
generated_at: "2026-06-28T07:50:34.470652+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma Q3 net loss $4.6M; Phase 2b enrollment underway

## Summary
- Net loss of $4.6M ($0.46/diluted share) for Q3 2021 vs. $1.3M ($0.21) in Q3 2020.
- Cash balance $14.5M as of Sep 30, 2021; R&D spend $1.1M (up from $0.7M) on Phase 2b costs.
- Phase 2b trial for C. difficile infection (ibezapolstat) enrollment started; completion expected Q3 2022.
- Phase 2a data showed 100% clinical cure, 100% sustained cure, beneficial microbiome changes.
- New collaboration with Leiden University to study DNA pol IIIC enzyme mechanism of action.

## SEC filing metadata
- accession: 0001104659-21-139573
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2021-11-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465921139573/0001104659-21-139573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465921139573/tm2133025d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-139573
- JSON: https://secwatch.observer/filing/0001104659-21-139573.json
- Plain text: https://secwatch.observer/filing/0001104659-21-139573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.